PDCD1 and cancer: Although most patients do not respond to these immunotherapies, therapeutic antibodies against PD‐1, PD‐L1 or CTLA4 have markedly increased progression‐free survival and overall survival in various cancers, especially when combined with chemotherapy [109, 110, 111, 112].